Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,381 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07412301 | The Effect of Celiac Axis Stenosis on Morbidity After Pancreatoduodenectomy - A Prospective Study | active not recruiting | — | 99 | Larissa University HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05139602 | A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy | active not recruiting | Phase 2 | 210 | AbbVieINDUSTRY |
| 8 |
| Feb 13, 2026 |
| clinicaltrials |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer(RECITE) | completed | Phase 3 | 165 | AmgenINDUSTRY | 20 | Feb 11, 2026 | clinicaltrials |
| NCT03710603 | Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma(Perseus) | active not recruiting | Phase 3 | 709 | Stichting European Myeloma NetworkNETWORK | 13 | Feb 10, 2026 | clinicaltrials |
| NCT05501886 | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)(VIKTORIA-1) | active not recruiting | Phase 3 | 701 | Celcuity IncINDUSTRY | 23 | Feb 10, 2026 | clinicaltrials |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | recruiting | Phase 3 | 550 | Jazz PharmaceuticalsINDUSTRY | 15 | Feb 10, 2026 | clinicaltrials |
| NCT02308085 | Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer(POSITIVE) | active not recruiting | N/A | 518 | ETOP IBCSG Partners FoundationNETWORK | 22 | Feb 9, 2026 | clinicaltrials |
| NCT03275285 | Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients(IKEMA) | completed | Phase 3 | 302 | SanofiINDUSTRY | 16 | Feb 9, 2026 | clinicaltrials |
| NCT03374085 | A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | terminated | Phase 1 / Phase 2 | 200 | CelgeneINDUSTRY | 11 | Feb 9, 2026 | clinicaltrials |
| NCT02152631 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer(JUNIPER) | active not recruiting | Phase 3 | 453 | Eli Lilly and CompanyINDUSTRY | 21 | Feb 6, 2026 | clinicaltrials |
| NCT07389408 | A Prospective, Multicenter Registry to Observe the Treatment Patterns, Clinical Outcomes, and Decision-Making in Patients With Early Breast Cancer Eligible for EndoPredict® Testing(PRELUDE) | recruiting | — | 2,000 | National and Kapodistrian University of AthensOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05419388 | A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma | completed | Phase 2 | 93 | Hoffmann-La RocheINDUSTRY | 10 | Feb 4, 2026 | clinicaltrials |
| NCT06981143 | Oncologists' Perceptions on Physical Activity and Exercise | completed | — | 606 | University of ThessalyOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT02246621 | A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer(MONARCH 3) | active not recruiting | Phase 3 | 493 | Eli Lilly and CompanyINDUSTRY | 22 | Feb 3, 2026 | clinicaltrials |
| NCT06697197 | A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 413 | Bristol-Myers SquibbINDUSTRY | 9 | Feb 3, 2026 | clinicaltrials |
| NCT02394626 | Surgery for Recurrent Glioblastoma(RESURGE) | recruiting | Phase 2 | 120 | Insel Gruppe AG, University Hospital BernOTHER | 9 | Feb 2, 2026 | clinicaltrials |
| NCT04414475 | A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. | recruiting | Phase 2 | 127 | Karyopharm Therapeutics IncINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT04294810 | A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer(SKYSCRAPER-01) | completed | Phase 3 | 620 | Hoffmann-La RocheINDUSTRY | 23 | Jan 30, 2026 | clinicaltrials |
| NCT03215030 | A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma(iinnovate-1) | terminated | Phase 1 / Phase 2 | 272 | Teva Branded Pharmaceutical Products R&D LLCINDUSTRY | 16 | Jan 29, 2026 | clinicaltrials |
| NCT02003924 | Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer(PROSPER) | completed | Phase 3 | 1,401 | PfizerINDUSTRY | 32 | Jan 27, 2026 | clinicaltrials |
| NCT05855200 | Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | recruiting | Phase 3 | 892 | GlaxoSmithKlineINDUSTRY | 28 | Jan 23, 2026 | clinicaltrials |
| NCT03873402 | A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer | active not recruiting | Phase 3 | 437 | Bristol-Myers SquibbINDUSTRY | 14 | Jan 21, 2026 | clinicaltrials |
| NCT02411448 | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)(RELAY) | active not recruiting | Phase 3 | 545 | Eli Lilly and CompanyINDUSTRY | 14 | Jan 16, 2026 | clinicaltrials |
| NCT05169567 | Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer(postMONARCH) | active not recruiting | Phase 3 | 368 | Eli Lilly and CompanyINDUSTRY | 17 | Jan 16, 2026 | clinicaltrials |
| NCT04266301 | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)(STIMULUS-MDS2) | terminated | Phase 3 | 530 | Novartis PharmaceuticalsINDUSTRY | 36 | Jan 13, 2026 | clinicaltrials |
| NCT05172596 | PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | terminated | Phase 2 | 146 | Novartis PharmaceuticalsINDUSTRY | 14 | Jan 13, 2026 | clinicaltrials |
| NCT05353257 | A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer | active not recruiting | Phase 3 | 511 | Shanghai Henlius BiotechINDUSTRY | 11 | Jan 13, 2026 | clinicaltrials |
| NCT04468984 | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis(TRANSFORM-2) | active not recruiting | Phase 3 | 330 | AbbVieINDUSTRY | 30 | Jan 9, 2026 | clinicaltrials |
| NCT07328087 | COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer(COLONYVAQ™-CRC) | recruiting | Early Phase 1 | 12 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05002569 | A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma(RELATIVITY-098) | terminated | Phase 3 | 1,093 | Bristol-Myers SquibbINDUSTRY | 25 | Jan 8, 2026 | clinicaltrials |
| NCT07316361 | GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer(GYNORYLAQ™) | enrolling by invitation | Early Phase 1 | 40 | Biogenea Pharmaceuticals Ltd.INDUSTRY | 1 | Jan 7, 2026 | clinicaltrials |
| NCT01208766 | Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma(HO95) | completed | Phase 3 | 1,503 | Stichting Hemato-Oncologie voor Volwassenen NederlandOTHER | 16 | Jan 6, 2026 | clinicaltrials |
| NCT02998528 | A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)(CheckMate 816) | completed | Phase 3 | 505 | Bristol-Myers SquibbINDUSTRY | 15 | Jan 6, 2026 | clinicaltrials |
| NCT06737211 | Optimizing Postoperative Nutrition in Colorectal Surgery(OPTI-NUTRICS) | completed | N/A | 200 | National and Kapodistrian University of AthensOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT05740566 | Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer(DeLLphi-304) | active not recruiting | Phase 3 | 509 | AmgenINDUSTRY | 31 | Jan 5, 2026 | clinicaltrials |
| NCT07316075 | Multicenter Study on Cardiovascular and Metabolic Complications in Patients With Biochemically Silent Pheochromocytomas and Paragangliomas | enrolling by invitation | — | 50 | Laikο General Hospital, AthensOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05952037 | A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia | active not recruiting | Phase 2 | 114 | BeOne MedicinesINDUSTRY | 9 | Jan 2, 2026 | clinicaltrials |
| NCT03602859 | A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer(FIRST) | active not recruiting | Phase 3 | 1,400 | Tesaro, Inc.INDUSTRY | 19 | Dec 31, 2025 | clinicaltrials |
| NCT04480814 | Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC | completed | — | 30 | Pharmassist LtdINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04490564 | Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma | completed | — | 135 | Pharmassist LtdINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT05704049 | A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma(IZALCO) | active not recruiting | Phase 2 | 118 | SanofiINDUSTRY | 7 | Dec 29, 2025 | clinicaltrials |
| NCT07022938 | Nutritional Supplement for Treating Chemotherapy Induced Neuropathy | completed | Phase 4 | 71 | Aristotle University Of ThessalonikiOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT05609968 | Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) | active not recruiting | Phase 3 | 614 | Merck Sharp & Dohme LLCINDUSTRY | 25 | Dec 24, 2025 | clinicaltrials |
| NCT03997123 | Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC(CAPItello-290) | active not recruiting | Phase 3 | 923 | AstraZenecaINDUSTRY | 30 | Dec 22, 2025 | clinicaltrials |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy(CONTACT-01) | completed | Phase 3 | 366 | Hoffmann-La RocheINDUSTRY | 15 | Dec 22, 2025 | clinicaltrials |
| NCT03180736 | Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex(EMN14) | completed | Phase 3 | 304 | Stichting European Myeloma NetworkNETWORK | 10 | Dec 19, 2025 | clinicaltrials |
| NCT04446117 | Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC(CONTACT-02) | active not recruiting | Phase 3 | 575 | ExelixisINDUSTRY | 27 | Dec 18, 2025 | clinicaltrials |
| NCT07292246 | A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)(ATHENA I) | recruiting | N/A | 15 | Vasileios KallesOTHER | 1 | Dec 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials